640 related articles for article (PubMed ID: 12644539)
21. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras K; Rubin K; Sjöblom T; Buchdunger E; Sjöquist M; Heldin CH; Ostman A
Cancer Res; 2002 Oct; 62(19):5476-84. PubMed ID: 12359756
[TBL] [Abstract][Full Text] [Related]
23. Role of E2F and ERK1/2 in STI571-mediated smooth muscle cell growth arrest and cyclin A transcriptional repression.
Sanz-González SM; Castro C; Pérez P; Andrés V
Biochem Biophys Res Commun; 2004 May; 317(4):972-9. PubMed ID: 15094364
[TBL] [Abstract][Full Text] [Related]
24. Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells.
Uhrbom L; Hesselager G; Ostman A; Nistér M; Westermark B
Int J Cancer; 2000 Feb; 85(3):398-406. PubMed ID: 10652433
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
Kłosowska-Wardęga A; Hasumi Y; Åhgren A; Heldin CH; Hellberg C
Melanoma Res; 2011 Feb; 21(1):57-65. PubMed ID: 20975605
[TBL] [Abstract][Full Text] [Related]
26. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
28. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
29. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
[TBL] [Abstract][Full Text] [Related]
30. Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
George D
Adv Exp Med Biol; 2003; 532():141-51. PubMed ID: 12908555
[TBL] [Abstract][Full Text] [Related]
31. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
[TBL] [Abstract][Full Text] [Related]
32. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
33. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Podtcheko A; Ohtsuru A; Tsuda S; Namba H; Saenko V; Nakashima M; Mitsutake N; Kanda S; Kurebayashi J; Yamashita S
J Clin Endocrinol Metab; 2003 Apr; 88(4):1889-96. PubMed ID: 12679488
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
35. ARG tyrosine kinase activity is inhibited by STI571.
Okuda K; Weisberg E; Gilliland DG; Griffin JD
Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
Katayama R; Huelsmeyer MK; Marr AK; Kurzman ID; Thamm DH; Vail DM
Cancer Chemother Pharmacol; 2004 Jul; 54(1):25-33. PubMed ID: 15108021
[TBL] [Abstract][Full Text] [Related]
38. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits.
Leppänen O; Rutanen J; Hiltunen MO; Rissanen TT; Turunen MP; Sjöblom T; Brüggen J; Bäckström G; Carlsson M; Buchdunger E; Bergqvist D; Alitalo K; Heldin CH; Ostman A; Ylä-Herttuala S
Circulation; 2004 Mar; 109(9):1140-6. PubMed ID: 14769706
[TBL] [Abstract][Full Text] [Related]
39. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
Kübler HR; van Randenborgh H; Treiber U; Wutzler S; Battistel C; Lehmer A; Wagenpfeil S; Hartung R; Paul R
Prostate; 2005 Jun; 63(4):385-94. PubMed ID: 15617027
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
